The Diabetes Educator

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Want, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Want, L. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
The Diabetes Educator, Vol. 34, No. 1 suppl, 11S-17S (2008)
DOI: 10.1177/0145721707313940
© 2008 American Association of Diabetes Educators; Published by SAGE Publications

FEATURES

Optimizing Treatment Success With an Amylin Analogue

Laura L. Want, MS, RN, BC-ADM, CDE

From MedStar Research Institute, Washington, DC.

Correspondence to Laura L. Want, MS, RN, BC-ADM, CDE (Laurie.Want{at}Medstar.net).

Diabetes affects approximately 18 million adults in the United States. Diabetes increases the risk of microvascular and macrovascular complications, such as nerve neuropathy, retinopathy, nephropathy, and cardiovascular disease. Intensive diabetes management reduces the risk of complications but presents numerous challenges in clinical practice. In the natural course of type 2 diabetes β cell function declines over time and may necessitate frequent medication adjustment. Oral antihyperglycemic medications may lose efficacy over time and may induce intolerable adverse events. Some medications for diabetes can cause weight gain, even if patients exercise and watch their food intake. Furthermore, patients with type 1 diabetes may experience frequent blood glucose fluctuations despite optimizing their use of insulin. Hypoglycemia is a common adverse effect of intensive diabetes management. Pramlintide as an adjunct to insulin therapy is useful for treating both type 1 and type 2 diabetes to improve control of postprandial glucose. To ensure maximal efficacy of pramlintide with minimal adverse events, it is extremely important that diabetes educators thoroughly understand pramlintide's mode of action, indications, appropriate patient selection, required insulin dose adjustments, and provide careful patient instruction.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?